title: Severe neutropenia and post-hepatitis C cirrhosis treatment: is interferon dose adaptation at once necessary?
authors.forename: C
authors.initials: C
authors.lastname: Renou
authors.forename: A
authors.initials: A
authors.lastname: Harafa
authors.forename: R
authors.initials: R
authors.lastname: Bouabdallah
authors.forename: C
authors.initials: C
authors.lastname: Dematteï
authors.forename: C
authors.initials: C
authors.lastname: Cummins
authors.forename: H
authors.initials: H
authors.lastname: Rifflet
authors.forename: P
authors.initials: P
authors.lastname: Muller
authors.forename: E
authors.initials: E
authors.lastname: Ville
authors.forename: J
authors.initials: J
authors.lastname: Bertrand
authors.forename: T
authors.initials: T
authors.lastname: Benderitter
authors.forename: P
authors.initials: P
authors.lastname: Halfon
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000008:administration & dosage* / Q000009:adverse effects* / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D005260:Female; D006526:Hepatitis C / Q000150:complications*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage* / Q000627:therapeutic use; D008103:Liver Cirrhosis / Q000188:drug therapy* / Q000821:virology*; D008297:Male; D008875:Middle Aged; D009503:Neutropenia / Q000139:chemically induced*; D011994:Recombinant Proteins
chemical_list: D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins